Abstract The actions of glucocorticoids are mediated, in part, by 11b-hydroxysteroid dehydrogenase 1 (11b-HSD1), which amplifies their effects at the pre-receptor level by converting cortisone to cortisol. Glucocorticoids, such as dexamethasone, inhibit vascular smooth muscle cell proliferation; however, the role of 11b-HSD1 in this response remains unknown. Accordingly, we treated human coronary artery smooth muscle cells (HCSMC) with dexamethasone (10 -9 -10 -6 mol/l) and found that after 72 h dexamethasone increased 11b-HSD1 expression (14.16 ± 1.6-fold, P \ 0.001) and activity (6.21 ± 1.2-fold, P \ 0.001) in a doseand time-dependent manner, which was dependent upon glucocorticoid receptor (GR) activation and C/EBPb and C/ EBPd signaling. As glucocorticoids are known to negatively regulate GR expression, we examined the effect of decreasing 11b-HSD1 expression on GR expression. In HCSMC transfected with 11b-HSD1 siRNA, GR expression was increased; this effect was associated with protein kinase A activation and CREB phosphorylation. To examine the role of 11b-HSD1 in HCSMC proliferation, we decreased 11b-HSD1 expression and stimulated cells with platelet-derived growth factor (PDGF) (10 ng/ml). Decreased 11b-HSD1 expression was associated with increased cell proliferation in the absence of PDGF compared to scrambled control-transfected cells (236.10 ± 13.11%, n = 4, P \ 0.001) and this effect was augmented by PDGF. Furthermore, the inhibitory effect of dexamethasone on cellular proliferation was abrogated in 11b-HSD1 siRNA-transfected HCSMC. Downregulation of 11b-HSD1 was associated with decreased p27 kip1 expression and increased phosphorylated retinoblastoma protein, consistent with a proliferative response. These findings suggest that 11b-HSD1 plays a role in the effects of glucocorticoids on vascular smooth muscle cell phenotype.
Introduction
Glucocorticoids have been shown to modulate vascular reactivity, the response to injury, and atherogenesis. These effects are mediated by glucocorticoid binding to, and activation of, cognate intracellular glucocorticoid receptors (GR) [1] . Glucocorticoids limit vascular remodeling and neointimal proliferation following vascular injury in part, by inhibiting vascular smooth muscle cell proliferation [2] [3] [4] [5] [6] . Local application of dexamethasone to rat carotid arteries following balloon injury has been shown to abrogate neointimal proliferation compared to untreated vessels [7] . Similar studies performed in mouse femoral arteries using a drug-eluting polymer cuff revealed that this finding was associated with vascular atrophy owing to a decreased number of vascular smooth muscle cells [8] . Mechanistically, dexamethasone has been shown to affect these responses by inducing cell cycle arrest at the G1 phase in vascular smooth muscle cells [9, 10] .
In mammalian blood vessels, local glucocorticoid concentrations are regulated at the pre-receptor level by the two isozymes of 11b-hydroxysteroid dehydrogenases (11b-HSDs), 11b-HSD1 and 11b-HSD2 [11] . The 11b-HSDs are microsomal enzymes of the short-chain alcohol dehydrogenase superfamily that interconvert active glucocorticoids to their inert 11-keto forms [11] . While 11b-HSD2 is expressed in the vascular endothelium and converts active glucocorticoids to their inactive 11-ketosteroids, 11b-HSD1 is a low-affinity NADP(H)-dependent, predominant reductase that regenerates active 11b-hydroxy forms and is expressed mainly in vascular smooth muscle cells [12] [13] [14] .
Although not previously demonstrated in vascular smooth muscle cells, in adipocytes and transformed cell lines, it has been shown that glucocorticoids up-regulate expression of 11b-HSD1 through an indirect mechanism that involves members of the CCAAT/enhancer-binding protein (C/ EBP) family of transcription factors [15] [16] [17] [18] [19] [20] [21] [22] [23] . In this manner, glucocorticoids regulate 11b-HSD1 expression and, in turn, 11b-HSD1 serves to amplify the local response to glucocorticoids [12, [24] [25] [26] .
Experimental evidence has linked 11b-HSD1 to the effects of glucocorticoids on vascular remodeling. Increased 11b-HSD1 activity resulted in elevated glucocorticoid concentrations and inhibition of angiogenesis in murine injury and repair models while inhibition of 11b-HSD1 was found to decrease atherosclerosis in ApoE knockout mice through a mechanism that did not involve altering lipid profiles [27, 28] . To date, the role of 11b-HSD1 in mediating the effects of glucocorticoids in vascular smooth muscle cells and the mechanism(s) by which this occurs remains incompletely characterized. In this study, therefore, we hypothesized that glucocorticoids increase 11b-HSD1 expression in vascular smooth muscle cells and that 11b-HSD1 expression was necessary to mediate the response to mitogenic stimuli.
Materials and methods

Cell culture
Human coronary artery smooth muscle cells (HCSMC) (Lonza, Walkersville, MD and Promocell, Heidelberg, Germany) were maintained in smooth muscle cell basal medium (SmBM) supplemented with SmGM SingleQuots (Lonza), without antibiotics, at 37°C in 5% CO 2 . Cells were passaged twice weekly using 0.5% trypsin/EDTA, and experiments were performed on cells from passages 2-5. In selected studies, to decrease 11b-HSD1 expression, HCSMC were transfected with 40 nmol/l Stealth RNAi TM to 11b-HSD1 mRNA (Invitrogen, Carlsbad, CA) or scrambled control (Invitrogen) using Lipofectamine RNAi MAX (Invitrogen) in OptiMEM media (Invitrogen). After 4 h, transfection medium was replaced with full growth medium, and experiments were performed after 48 h. To decrease GR expression, HCSMC were transfected with 40 nmol/l Stealth RNAi TM to glucocorticoid receptor mRNA (Invitrogen) using the same protocol as for 11b-HSD1 transfection. To decrease C/EBPb and C/EBP/d expression, HCSMC were transfected with 40 nmol/l RNAi to C/EBPb mRNA (Ambion, Foster City, CA) or C/EBPd mRNA (Ambion), respectively, using the same protocol as for 11b-HSD1 transfection.
RNA extraction and qRT-PCR
Total RNA from HCSMC were extracted with the RNeasy kit (Qiagen, Germantown, MD), following the manufacturer's instructions. Samples were quantified and checked for purity and quality by A260/A280 measurements. cDNA was synthesized from 1-5 lg of each total RNA sample with random hexamers using the Superscript III FirstStrand Synthesis System for RT-PCR (Invitrogen) according to the manufacturer's instructions. Quantitative real-time PCR (qRT-PCR) was performed on an Applied Biosystems PRISM 7900 HT Sequence Detector (Foster City, CA). TaqMan Ò Gene Expression Assays for 11b-HSD1, GR, C/EBPb, C/EBP/d, and GAPDH were purchased from Applied Biosystems. PCR products were analyzed using the DDC t method with GAPDH as the endogenous control. Cycle parameters were 95°C for 15 min followed by 40 cycles at 95°C for 15 s, 58°C for 1 min, and 72°C for 1 min.
Western immunoblotting
Cells were lysed directly in RIPA buffer (sodium phosphate pH 7.2 10 mM, sodium chloride 150 mM, Triton X 100 1%, sodium deoxycholate 0.5%, and SDS 0.1%) supplemented with protease and phosphatase inhibitors and stored at -80°C before analysis. Protein samples (10-35 lg) were separated on 4-15% SDS-polyacrylamide gels and transferred to PVDF membranes. The membranes were incubated with antibodies to 11b-HSD1, 11b-HSD2, mineralocorticoid receptor, anti-C/EBPb (Abcam, Cambridge, MA); GR, C/EBPd, phospho-protein kinase A, protein kinase A a-subunit, cAMP Response Element Binding Protein (CREB), hexose-6-phosphate dehydrogenase (Santa Cruz, Santa Cruz, CA); or phospho-GR, phospho-CREB, p27 kip1 , phospho-Retinoblastoma protein (Rb)(Ser 608), (Cell Signaling, Danvers, MA) overnight at 4°C, and visualized using the ECL detection system (Amersham Biosciences), according to the manufacturer's instructions. The membranes were then stripped and reprobed with either a polyclonal rabbit anti-b-actin antibody (Sigma-Aldrich) or a polyclonal rabbit anti-b-tubulin antibody (Santa Cruz). A VersaDoc (BioRad) scanning system was used to quantitate band density.
11b-Hydroxysteroid dehydrogenase activity assay
The 11b-HSD1 activity was measured as previously described [29] with minor modifications. Briefly, HCSMC were incubated with 100 nmol/l cortisone and [1,2(n) 3 H]-cortisone (Amersham) for 8 h, after which steroids were extracted with dichloromethane and resolved by thin-layer chromatography on silica plates. Plates were imaged with iodine vapor, cortisone and hydrocortisone were identified and isolated from the plate, and the corresponding radioactivity was determined by scintillation counting (Beckman Coulter). Results were standardized by total cellular protein levels.
Protein kinase A activity assay Protein kinase A activity was measured using PepTag 
Proliferation assay
The HCSMC were serum-starved for 48 h in 0.2% fetal calf serum to synchronize the cells. After this time, cells were stimulated with 5% FCS and 10 ng/ml PDGF-BB in the presence or absence of dexamethasone (10 -7 mol/l). Cell proliferation was determined by measuring BrdU incorporation into the DNA of dividing cells using the BrdU Cell Proliferation Assay (Calbiochem, San Diego, CA), according to the manufacturer's instructions. Results were standardized by cell number. Cell viability was determined using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, Wisconsin) according to the manufacturer's directions.
Cell cytotoxicity and apoptosis assays
The ratio of dead-to-live cells was determined using the MultiTox-Fluor Cytotoxicity Assay (Promega), and caspase 3, 7 activity was quantified using the Caspase-Glo 3/7 Assay (Promega), according to the manufacturer's instructions.
Murine aorta isolation, immunohistochemistry, and immunofluorescence All procedures were approved by the Institutional Animal Care and Use Committee at Brigham and Women's Hospital and Harvard Medical School. Aortas were harvested from C57Bl/6 male mice (Charles River) of age 12-16 weeks. The vessels were irrigated with ice-cold phosphate-buffered saline until free of blood, dissected free of adventitia, and cut into 5 mm rings. The rings were placed in smooth muscle cell basal medium (Lonza) and incubated at 37°C in 5% CO 2 . To decrease 11bHSD-1 expression, 80 nmol/l Stealth RNAi TM to 11b-HSD1 mRNA (Invitrogen, Carlsbad, CA) or scrambled control (Invitrogen) and Lipofectamine RNAi MAX (Invitrogen) was added to the medium. At selected time points, the aortas were embedded in paraffin and 5 ln sections were analyzed by hematoxylin and eosin staining, immunohistochemistry or immunofluorescence as described previously [30, 31] using antibodies to 11b-HSD1 (abcam) and Ki67 (BD Biosciences), respectively.
Data analysis
All experiments were performed a minimum of three times at least in duplicate and data presented are expressed as mean ± standard error of the mean (SEM). The statistical significance of differences was determined by ANOVA followed by Bonferroni's pairwise comparison using GraphPad Prism 3.0 software (GraphPad Software, Inc, La Jolla, CA). A P value of \0.05 was considered significant.
Results
Dexamethasone increases 11b-HSD1 expression and activity
To determine the effect of dexamethasone on 11b-HSD1 expression in HCSMC, we first assessed steady-state levels of 11b-HSD1 mRNA. Dexamethasone increased 11b-HSD1 mRNA in a dose-dependent manner with the maximum effect observed at 10 -7 mol/l (6.5 ± 0.7-fold increase at 18 h vs. control, n = 3, P \ 0.01) (Fig. 1a) . As we saw no further increase in 11b-HSD1 mRNA levels with higher concentrations of dexamethasone, we elected to perform experiments on HCSMC treated with dexamethasone 10 -7 mol/l. Dexamethasone also increased 11b-HSD1 mRNA in a time-dependent manner with the maximum effect observed at 72 h (116 ± 36-fold increase vs. control, n = 3, P \ 0.01) (Fig. 1b) ; no further increase in mRNA levels was observed at 96 h. This finding was associated with an increase in 11b-HSD1 protein levels (14.6 ± 1.6-fold increase vs. control, n = 3, P \ 0.001) (Fig. 1c ) and 11b-HSD1 reductase activity (Fig. 1d) . We found that under these treatment conditions, there was no effect of dexamethasone on 11b-HSD2 or hexose-6-phosphate dehydrogenase protein expression ( Supplementary Fig. 1a , b).
The GR, C/EBPb, and C/EBPd modulate 11b-HSD1 expression To examine the role of GR activation on the dexamethasone-mediated increase in 11b-HSD1 expression, we first examined GR expression and phosphorylation. While dexamethasone treatment for 24 h decreased total GR protein levels by 45.3 ± 8.6% compared to control cells (n = 3, P \ 0.01) (Fig. 2a) , phosphorylation at Ser 211 was increased by 52.4 ± 17.3% compared to control (n = 3, P \ 0.05) (Fig. 2b) , indicating activation of the receptor. This increase in phospho-GR was transient, peaking at 24 h. In contrast, we found that under these conditions, dexamethasone had no effect on MR expression in HCSMC (Supplementary Fig. 1c ).
We next examined the effect of GR activation on expression of members of the CCAAT/enhancer-binding protein (C/EBP) family of transcription factors, as these have been shown to modulate 11b-HSD1 enzyme expression in other cell types [20] [21] [22] [23] . Dexamethasone increased C/EBPb (53.2 ± 11%, vs. control, n = 3, P \ 0.05) (Fig. 2c ) mRNA levels and transiently increased C/EBPb protein levels (80.2 ± 4.7% vs. control, n = 3, P \ 0.01) (Fig. 2d) . Dexamethasone also increased C/EBPd mRNA levels (241.1 ± 19% vs. control, n = 5, P \ 0.001) (Fig. 2e) , as well as C/EBPd protein levels (223.9 ± 6% vs. control, P \ 0.001) (Fig. 2f) .
Next, to demonstrate that GR activation was necessary for the observed increase in 11b-HSD1 expression, we transfected HCSMC with an siRNA to GR mRNA to decrease protein expression by 75.6% (n = 3, P \ 0.001) compared to scrambled control-transfected cells and examined the effect of GR downregulation on 11b-HSD1 expression. When HCSMC transfected with GR siRNA were treated with dexamethasone, we found a 46.5-fold (n = 3, P \ 0.001) decrease in 11b-HSD1 mRNA (Fig. 3a) and an 8.7-fold decrease (n = 3, P \ 0.001) in 11b-HSD1 protein levels (Fig. 3b) compared to scrambled control-transfected cells treated with dexamethasone. These data indicate that GR activation is necessary for the dexamethasone-dependent increase in 11b-HSD1 expression.
Similarly, to determine if the transcription factors C/EBPb or C/EBPd, which are activated by the GR, were necessary for the observed increase in 11b-HSD1 expression, we first transfected HCSMC with an siRNA to C/EBPb to decrease C/EBPb protein levels by 71.5% (n = 3, P \ 0.001) compared to scrambled control-transfected cells. Downregulation of C/EBPb attenuated the effect of dexamethasone on 11b-HSD1 mRNA (4.6-fold, Fold change (normalized to GAPDH) Fig. 1 Dexamethasone increases 11b-HSD1 expression and activity. Human coronary artery smooth muscle cells (HCSMC) a were treated with increasing concentrations of dexamethasone and 11b-HSD1 mRNA levels were determined by qRT-PCR after 18 h (n = 3). HCSMC were treated with dexamethasone (10 -7 mol/l) for 0-72 h and 11b-HSD1 b mRNA levels were determined by qRT-PCR (n = 3), c protein expression was examined by Western immunoblotting (n = 3), and d 11b-HSD1 activity was measured. (n = 3). Data are presented as mean ± SEM. A representative blot is shown.*P \ 0.01 versus UN, 0. UN treated; Dex dexamethasone n = 3, P \ 0.001) and protein levels (7.4-fold, n = 3, P \ 0.001) compared to scrambled control-transfected cells (Fig. 3c, d) . We next transfected HCSMC with an siRNA to C/EBPd, which decreased C/EBPd protein expression by 80.3% (n = 3, P \ 0.01), and found that downregulation of C/EBPd inhibited the dexamethasonemediated increase of 11b-HSD1 mRNA (2.1-fold, n = 3, P \ 0.001) and protein levels (2.0-fold, n = 3, P = 0.01) compared to scrambled control-transfected cells (Fig. 3c,  d ). Together, these data indicate that both C/EBPb and C/ EBPd are necessary to increase 11b-HSD1 mRNA and protein levels in response to dexamethasone. Fig. 3 The GR, C/EBPb, and C/EBPd regulate the dexamethasonemediated increase in 11b-HSD1 expression. HCSMC were transfected with an siRNA to decrease GR expression or a scrambled control (SS), treated with dexamethasone (10 -7 mol/l), and a 11b-HSD1 mRNA levels were determined by qRT-PCR (n = 3) and b protein expression by Western immunoblotting (n = 3). HCSMC were transfected with an siRNA to decrease C/EBPb or C/EBPd expression, respectively, or a scrambled control, treated with dexamethasone (10 -7 mol/l), and c 11b-HSD1 mRNA levels were determined by qRT-PCR (n = 3) and d protein expression by Western immunoblotting (n = 3). mRNA and protein levels were determined. Data are presented as mean ± SEM and representative blots are shown. *P \ 0.001 versus SS, **P \ 0.001 versus SS ? Dex 11b-HSD1 is involved in the regulation of GR expression As GR expression is negatively regulated by its ligand, and 11b-HSD1 activity is an important pre-receptor mechanism to generate GR ligand, we also examined the effect of decreasing the expression of 11b-HSD1 on GR expression. When we transfected HCSMC with an siRNA to 11b-HSD1 to decrease protein expression by 64% (P \ 0.01), we found that compared to scrambled control-transfected cells, downregulation of 11b-HSD1 resulted in an increase in GR protein expression (Fig. 4a) . Furthermore, while dexamethasone decreased GR protein expression in scrambled control-transfected cells, this response was abrogated in 11b-HSD1 siRNA-transfected HCSMC suggesting that 11b-HSD1 plays a role in the dexamethasonemediated downregulation of GR expression (Fig. 4a) .
CREB has been shown to regulate transcription of the GR gene in response to glucocorticoid levels [26] . To determine if 11b-HSD1 modulated GR expression by influencing activation of CREB, we first examined expression and activity of protein kinase A which is known to phosphorylate and activate CREB. In scrambled controltransfected HCSMC, dexamethasone decreased phosphorylation of protein kinase A, which was associated with a decrease in protein kinase A activity (Fig. 4b, c) . Interestingly, 11b-HSD1 siRNA-transfected HCSMC demonstrated increased protein kinase A phosphorylation and activity compared to scrambled control-transfected cells, and this effect was not influenced significantly by dexamethasone (Fig. 4b, c) . In line with these findings, dexamethasone treatment decreased CREB phosphorylation in scrambled control-transfected cells, while HCSMC with decreased 11b-HSD1 expression demonstrated increased CREB phosphorylation (Fig. 4d) . These findings suggest that 11b-HSD1 expression influences CREB activation as a mechanism by which to regulate GR expression.
Role of 11b-HSD1 in PDGF-stimulated HCSMC proliferation
Glucocorticoids have been shown to regulate vascular smooth muscle cell proliferation; however, the role of 11b-HSD1 in this process remains incompletely characterized. We, therefore, examined the effect of dexamethasone on HCSMC proliferation in cells with normal 11b-HSD1 expression and decreased 11b-HSD1 expression. After 48 h of serum starvation, HCSMC were stimulated with 5% serum and recombinant human PDGF-BB (10 ng/ml) in the presence or absence of dexamethasone (10 -7 mol/l). In scrambled control-transfected HCSMC, PDGF-BB increased proliferation as determined by BrdU incorporation (100.38 ± 14.72 vs. 581.32 ± 11.87 arb. units/cell number, n = 4, P \ 0.001), while the addition of dexamethasone to PDGF-BB-stimulated cells decreased cell proliferation (253.42 ± 7.15 arb. units/cell number, n = 4, P \ 0.001). In 11b-HSD1 siRNA-transfected HCSMC, there was an increase in proliferation compared to scrambled control-transfected cells under basal conditions (100.38 ± 14.72 vs. 237.10 ± 12.72 arb. (Fig. 5) . To demonstrate the potential in vivo relevance of these findings, we harvested aortas from C57Bl/6 wild-type mice (n = 12), sectioned the vessels to 5 mm rings, transfected them with siRNA to 11b-HSD1 to decrease protein expression by 52% (P \ 0.01) or a scrambled control (Fig. 6a) , and maintained them in culture for up to 72 h. In selected sections, we stimulated the rings with recombinant rat PDGF-BB (10 ng/ml) in the presence or absence of dexamethasone (10 -7 mol/l). Following stimulation with PDGF-BB, co-incubation with dexamethasone decreased cell proliferation, determined by the average number of Ki67 positive fluorescent cells/10 high powered fields (hpf), in scrambled control-transfected aortas (18.21 ± 5.45 vs. 7.67 ± 3.66 cells/hpf, P \ 0.01). Similar to what was observed with HCSMC, in PDGFstimulated aorta sections transfected with 11b-HSD1 siRNA that were co-incubated with dexamethasone, there was an attenuated effect in inhibiting proliferation (30.11 ± 3.87 vs. 24.55 ± 4.33 cells/hpf, P = 0.07) (Fig. 6b) .
We next sought to determine a mechanism by which to explain the observed differences in proliferation between HCSMC with normal levels of 11b-HSD1 expression and those with decreased 11b-HSD1 expression. We found that there was no difference between the ratio of dead-to-live cells between scrambled control-transfected HCSMC and those with decreased 11b-HSD1 expression (0.93 ± 0.08 vs. 0.93 ± 0.15, n = 4, P = NS), and we found no difference in apoptosis between the two groups (17.54 ± 6.80 vs. 17.53 ± 4.68 relative light units, n = 4, P = NS). These results suggest that the observed differences in cell proliferation could not be attributed to an increase in cell death or apoptosis.
Next, we examined expression of p27 kip1 and its downstream target phosphorylated retinoblastoma (Rb) protein as both of these regulate the G1-phase of the cell cycle, are subject to control by glucocorticoids and have been implicated in mediating vascular smooth muscle cell proliferation. In accordance with previously published reports, we found in scrambled control-transfected cells that PDGF-BB decreased p27 kip1 expression and increased phosphorylation of Rb at Ser608, consistent with progression through the cell cycle and proliferation; the addition of dexamethasone to PDGF-stimulated cells increased p27 kip1 expression and decreased phosphorylation of Rb, indicating a cell cycle block and inhibition of proliferation. In contrast, in 11b-HSD1 siRNA-transfected HCSMC, p27 kip1 expression was decreased and phosphorylation of Rb was increased compared to scrambled-control transfected cells under basal conditions. Here, stimulation with PDGF resulted in a modest, further decrease in p27 kip1 expression and the addition of dexamethasone resulted in a minor increase in p27 kip1 expression and corresponding decrease in phospho-Rb (Fig. 7a, b) . Taken together, these data demonstrate that 11b-HSD1 participates in glucocorticoidmediated inhibition of HCSMC proliferation in response to PDGF, in part, by modulating p27 kip1 expression and Rb phosphorylation to facilitate the cell cycle block at G1.
Discussion
In these studies, we found that dexamethasone increases 11b-HSD1 expression and activity in HCSMC in a GRdependent manner to regulate cell proliferation through p27 kip1 and Rb. We also identified a role for 11b-HSD1 in the regulation of GR expression. There are several earlier reports that demonstrate that glucocorticoids increase 11b-HSD1 expression in non-vascular cells and one study showing an increase in 11b-HSD1 mRNA levels in rat aortic smooth muscle cells [32, 33] . Our studies now extend these observations to human vascular smooth muscle cells. Furthermore, we demonstrate that 11b-HSD1 expression in response to glucocorticoids is dependent upon GR activation as evidenced by the lack of increase in 11b-HSD1 expression in HCSMC transfected with siRNA to GR. The time course of upregulation of 11b-HSD1 expression observed in our studies is consistent with indirect regulation of the 11b-HSD1 promoter by glucocorticoids, paralleling previous reports in human fibroblasts and in A549 cells [15, 23] . The transcriptional activity of glucocorticoids has been linked to the C/EBP family of transcription factors that interact with either the GR or target gene promoters to promote transcription. In addition, C/EBPs, primarily C/EBPb, mediate the effect of glucocorticoids by inducing transcription of genes that lack GR binding sites [34] [35] [36] . We find that C/EBPb, and to a lesser extent C/EBPd, are important for the dexamethasone-mediated increase in 11b-HSD1 expression in HCSMC. Our findings are in accord with previously published studies that established the central role of C/EBPs in the regulation of 11b-HSD1 transcription in liver, lung, and adipose cells [20] [21] [22] [23] . Fig. 7 11b-HSD1 influences the expression of cell cycle regulators in response to PDGF and dexamethasone. HCSMC were transfected with an siRNA to decrease 11b-HSD1 expression, synchronized by serum starvation (0.2% serum) for 48 h, and stimulated with 5% fetal calf serum and platelet-derived growth factor-BB (PDGF) (10 ng/ml) in the presence or absence of dexamethasone (10 -7 mol/l). Expression of a p27 kip1 (n = 3) and b phosphorylation of retinoblastoma protein (phospho-Rb) at Ser608 (n = 3) were determined by Western immunoblotting. Representative blots are shown It is also recognized that glucocorticoids negatively regulate expression of the GR [37, 38] . In our studies, we demonstrate 11b-HSD1 mediates dexamethasone-mediated downregulation of GR expression in HCSMC. Here, we showed that decreased 11b-HSD1 expression, which would decrease levels of active glucocorticoids, was associated with an increase in GR expression compared to control cells and cells exposed to dexamethasone, indicating that 11b-HSD1 plays a role in the regulation of GR expression under ambient conditions. It has been demonstrated that GR expression is controlled at the transcriptional level by the phosphorylation state of CREB [39] . We found that downregulation of GR was associated with decreased CREB phosphorylation in cells with normal levels of 11b-HSD1. Interestingly, we also observed that when we decreased 11b-HSD1 expression, which resulted in an increase in GR expression, there was an associated increase in phospho-CREB levels. We further examined protein kinase A activation as a mechanism of CREB phosphorylation, as a earlier study demonstrated that GR transcription is dependent on protein kinase A signaling [40] . Here, we found that increased activation of protein kinase A was associated with the increase in CREB phosphorylation.
As glucocorticoids modulate vascular smooth muscle cell phenotype, we examined the role of 11b-HSD1 in regulating the effect of dexamethasone on vascular smooth muscle cell proliferation. While prolonged exposure to glucocorticoids inhibits proliferation of cultured vascular smooth muscle cells by inducing a cell cycle arrest at the G1 phase [9, 10, 41, 42] , the role of 11b-HSD1 in mediating this effect is less well defined. In earlier studies performed in an osteosarcoma cell line transfected with 11b-HSD1, expression of 11b-HSD1 was associated with decreased cell proliferation that was attributed to metabolism of endogenous glucocorticoids to increase cortisol levels [43] . This observation supports our findings that HCSMC with decreased 11b-HSD1 expression demonstrate increased proliferation under basal conditions and in response to PDGF as compared to cells with normal 11b-HSD1 expression. The diminished inhibitory effect of dexamethasone in cells with decreased 11b-HSD1 expression suggests that endogenous metabolism of glucocorticoids is involved in modulating cell proliferation. Furthermore, the translational relevance of these findings was confirmed ex vivo in murine aortas with decreased 11b-HSD1 expression.
The precise mechanism by which glucocorticoids inhibit cell proliferation is not yet known; however, it has been shown that glucocorticoids influence the expression of cyclin-dependent kinases and -dependent kinase inhibitors, including p27 kip1 [10] . Accordingly, we investigated the role of 11b-HSD1 in modulating the expression of p27 kip1 and the phosphorylation state of Rb. Rb, which lies downstream of p27 kip1 , has also been linked to the inhibitory effects of dexamethasone on vascular smooth muscle cell proliferation [10, 41, 44] . Consistent with our findings on the effects of 11b-HSD1 expression on proliferation, we found that decreased 11b-HSD1 expression was associated with a downregulation of the cyclin-dependent kinase inhibitor p27 kip1 , leading to increased phosphorylation of Rb to promote exit from G1 and cell proliferation.
Taken together, our findings indicate that glucocorticoids stimulate a ''feed-forward'' mechanism to enhance local generation of active glucocorticoids by upregulating the expression and activity of 11b-HSD1 in HCSMC. This increase in 11b-HSD1 expression further serves to regulate the actions of GR activation by modulating GR expression through a protein kinase A-CREB-dependent mechanism. Although this may seem counterintuitive, such a signaling mechanism may serve to redirect glucocorticoids to activate the mineralocorticoid receptor in cells and tissues that do not express 11b-HSD2. In vascular smooth muscle cells, evidence exists that this mechanism is operative [45] . In HCSMC, we also demonstrate that 11b-HSD1 expression is also necessary to mediate cellular proliferation under basal and growth factor-stimulated conditions. These findings suggest that 11b-HSD1 may serve as a target for therapeutic intervention in vascular disease states characterized by excess vascular smooth muscle cell proliferation, such as restenosis. In fact, selective 11b-HSD1 inhibition has already been shown to limit atherosclerotic neointima formation, and 11b-HSD1 -/-mice have a cardioprotective phenotype that is characterized by increased angiogenesis following injury [27, 28] . Our findings suggest further that systemic administration of novel 11b-HSD1 inhibitors that are currently under investigation for obesity and diabetes may have effects on the vasculature [28, [46] [47] [48] [49] .
